Merck Frosst
Patients & Caregivers Contact Us Français
Patients & CaregiversContact UsFrançais
Home

VIOXX® Information Center

Statement

Merck Frosst Statement Regarding Authorization of Limited Class of VIOXX Users in Quebec 09/11/2006
An Open Letter from Merck ( PDF* 1.8MB ) 15/12/2005
Merck & Co., Inc. Response to an Editorial Posted on the New England Journal of Medicine Web Site 08/12/2005

Press Release

The Supreme Court of Canada Will Not Review the Saskatchewan Court of Appeal Judgment Overturning a Class Certification Order in VIOXX® Action (  PDF* 27KB ) 22/10/2009
Ontario Court Grants Merck Time to Appeal Class Certification of Vioxx Action 11/05/2009
Court of Appeal for Saskatchewan Allows Merck's Appeal and Overturns Class Certification of Vioxx Action 30/03/2009
Merck to Seek Appellate Review of Class Certification Decision in VIOXX® Proceedings in Ontario 28/07/2008
Merck to Seek Appellate Review of Class Certification Decision in VIOXX® Proceedings in Saskatchewan 30/05/2008
Merck wins appeal in VIOXX® case 14/05/2008
Merck to Seek Appellate Review of Class Certification Decision in VIOXX® Proceedings in Saskatchewan 20/02/2008
New Jersey High Court Denies Nationwide Class-Action Status to Insurance Companies Seeking VIOXX® Reimbursements 06/09/2007
Merck & Co. Wins Alabama VIOXX® Product Liability Case 15/12/2006
Merck & Co. Wins Federal VIOXX® Product Liability Case -- Dedrick v. Merck & Co. 13/12/2006
Statement Regarding Dismissal of Personal Injury Class-Action Lawsuit 22/11/2006
Merck Wins Federal VIOXX® Product Liability Case : Mason v. Merck & Co 15/11/2006
Merck & Co., Inc. Wins Federal VIOXX® Product Liability Case 17/02/2006
Merck to Appeal Verdict in Texas VIOXX® Product Liability Case 19/08/2005
Merck Announces Voluntary Worldwide Withdrawal of VIOXX® 30/09/2004

General Information

Where Patients Come First
Merck Frosst and Vioxx®: what you need to know
Dr. François Bertrand, Executive Director of Medical Research at Merck Frosst
Response to Article in the Lancet ( PDF* 25KB )
VIOXX® Timeline ( PDF* 28KB )
Timeline of Epidemiological Studies Involving VIOXX® or NSAIDs ( PDF* 39KB )
Overview Chart of Major VIOXX® Research Studies ( PDF* 30KB )
Video Message

Dr. Peter Kim, President, Merck Research Laboratories, Merck and Co., Inc.
Video Message on the Scientific Process Surrounding VIOXX®

56Kb (Dial-up)
256Kb (Cable/DSL)
Audio Only

Printer friendly
Email a friend

This site is for residents of Canada. / This site was updated on February 5, 2010.